Beranda › Kanker Payudara › Tennessee › Memphis
Uji klinis Kanker Payudara di Memphis, TN
22 studi untuk Kanker Payudara mencari peserta di lokasi sekitar Memphis (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
Menerima pesertaFase 1/2
- The West Cancer Center, Memphis
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Menerima pesertaFase 1/2
- Baptist Cancer Center - Memphis, Memphis
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
Menerima pesertaFase 3
- Baptist Memorial Healthcare, Memphis
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
Menerima pesertaFase 2
- West Cancer Center, Germantown · 14 mi jauhnya
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Menerima peserta
- West Cancer Center, Germantown · 14 mi jauhnya
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Menerima pesertaFase 3
- Clinical Trial Site, Bartlett · 11 mi jauhnya
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Menerima pesertaFase 3
- The West Clinic, P.C. dba West Cancer Center, Germantown · 14 mi jauhnya
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Menerima pesertaFase 3
- Baptist Cancer Center, Memphis
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
Menerima pesertaFase 1/2
- The West Clinic, Germantown · 14 mi jauhnya
Post-Marketing Study for Early-Stage Low-Risk Breast Cancer Treatment Using ProSense® Cryoablation (ChoICE Trial)
Menerima peserta
- The West Clinic, PC dba West Cancer Center, Germantown · 14 mi jauhnya
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Menerima pesertaFase 3
- West Cancer Center, Germantown · 14 mi jauhnya
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Menerima pesertaFase 3
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
- Baptist Memorial Hospital and Cancer Center-Desoto, Southhaven · 12 mi jauhnya
- The West Clinic - Wolf River, Germantown · 14 mi jauhnya
- dan 1 lainnya
E-Mindfulness Approaches for Living After Breast Cancer
Menerima pesertaFase 3
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
- Baptist Memorial Hospital and Cancer Center-Desoto, Southhaven · 12 mi jauhnya
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Menerima pesertaFase 1/2
- The West Clinic, PLLC dba West Cancer Center, Germantown · 14 mi jauhnya
Familial Investigations of Childhood Cancer Predisposition
Menerima pesertaStudi observasional
- St. Jude Children's Research Hospital, Memphis
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Menerima pesertaFase 3
- The West Clinic, PLLC dba West Cancer Center, Germantown · 14 mi jauhnya
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Menerima pesertaStudi observasional
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
- Baptist Memorial Hospital for Women, Memphis
- Baptist Memorial Hospital and Cancer Center-Desoto, Southaven · 11 mi jauhnya
- dan 1 lainnya
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- Baptist (BHMCC), Memphis
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Menerima pesertaStudi observasional
- Massive Bio SYNERGY-AI site, Memphis
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Menerima pesertaFase 3
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Menerima pesertaFase 1
- Exelixis Clinical Site #11, Germantown · 14 mi jauhnya
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Menerima pesertaStudi observasional
- West Cancer Center, Germantown · 14 mi jauhnya
Uji klinis Kanker Payudara di kota lain
- New York City, NY136 studi
- Houston, TX126 studi
- Boston, MA112 studi
- Nashville, TN81 studi
- Los Angeles, CA73 studi
- Edison, NJ68 studi
- St. Louis, MO64 studi
- Queens, NY64 studi
- Durham, NC64 studi
- Chicago, IL59 studi
- Philadelphia, PA56 studi
- Dallas, TX55 studi
Studi lain di Memphis
- Kanker (semua jenis)31 studi
- Kanker Paru Non-Sel Kecil23 studi
- Kanker Paru18 studi
- Penyakit Sel Sabit18 studi
- Leukemia Limfoblastik Akut16 studi
- Leukemia Mieloid Akut15 studi
- Gagal Jantung13 studi
- Sarkoma Jaringan Lunak11 studi
- Melanoma11 studi
- Kanker Prostat11 studi
- Kanker Kolorektal11 studi
- Osteosarkoma10 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.